Generate Biomedicines (GENB) vs Xencor (XNCR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Xencor is the larger company by market cap ($1.80 billion vs $1.74 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GENB | XNCR |
|---|---|---|
| Share price | $13.57 | $24.26 |
| Market cap | $1.74B | $1.80B |
| 1-day change | -1.67% | -0.41% |
| YTD return | — | +58.46% |
| 1-year return | — | +101.66% |
| 5-year return | — | -36.94% |
| EPS (TTM) | $-2.44 | $-2.05 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $22.67 | $30.61 |
| 52-week low | $11.00 | $10.38 |
| Distance from 52-week high | -40.14% | -20.74% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +98.97% | +29.51% |
| Average volume | 1.03M | 1.30M |
| Shares outstanding | 128.35M | 74.35M |
| Employees | 312 | 260 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Generate Biomedicines
GENB stock →Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States. It uses protein-based modalities for drug development.
Healthcare · Biotechnology · 312 employees
About Xencor
XNCR stock →Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.
Healthcare · Biotechnology · 260 employees
GENB vs XNCR FAQ
Which is bigger, Generate Biomedicines or Xencor?
Xencor (XNCR) is larger, with a market capitalization of $1.80B compared with $1.74B for Generate Biomedicines (GENB).
Are Generate Biomedicines and Xencor in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.